Cellitas highlights cellular health research at aging conference

Cellitas participated in the 12th Aging Research and Drug Discovery Meeting, where it presented its polyamine-based cellular health approach to researchers and clinicians. The company pointed to published trial data, third-party testing, and scientific leadership as it engaged the aging research community in August 2025.

Why it matters: - Cellitas used the ARDD meeting to position its cellular health work inside one of aging research’s main scientific forums. - The company’s focus on autophagy and polyamine-based compounds ties into broader interest in how cells maintain function with age. - Published human data and third-party testing may matter to clinicians, researchers, and consumers evaluating longevity-related products.

What happened: - Cellitas participated in the 12th Aging Research and Drug Discovery Meeting, held Aug. 25-29, 2025. - Chief Medical Officer Dr. Lucy Jones and Scientific Advisory Board member Professor Ghada Alsaleh represented Cellitas at the meeting. - The event brought together researchers, clinicians, and organizations focused on aging biology, longevity medicine, and drug discovery. - Cellitas representatives discussed the company’s polyamine-based approach to cellular health with members of the aging research community.

The details: - The meeting featured more than 200 speakers across sessions on Longevity Medicine, Emerging Science & Technologies, and Physics in Aging Biology. - Nobel laureates Michael Levitt and Morten Meldal joined researchers from Stanford, Harvard Medical School, Buck Institute, Mayo Clinic, and the National Institute on Aging. - The scientific program also included companies working across longevity research, mixing academic and commercial perspectives. - Cellitas centers its work on autophagy, the body’s natural cellular renewal process. - The company’s research mentions spermidine, spermine, and arginine as compounds studied for roles in cellular maintenance. - A published six-month randomized controlled trial of the Cellitas formulation reported a 32% average increase in autophagy versus baseline. - The same trial reported no serious adverse events. - Each Cellitas batch is third-party tested. - Certificates of analysis are published for purity and potency. - Cellitas’ research leadership includes specialists covering clinical trials, infection, immunity, healthy aging, autophagy, immune-cell function, and age-related changes in cellular regulation.

Between the lines: - The ARDD appearance suggests Cellitas is trying to align its messaging with mainstream aging research rather than only wellness marketing. - The company is leaning on clinical data and testing transparency to support credibility in a crowded longevity field. - Bringing medical and advisory leaders to the meeting signals an effort to engage directly with the scientific community.

What's next: - Cellitas is likely to keep presenting its cellular health research to aging-focused audiences as the field expands. - The company’s next credibility test will be how its clinical evidence and product testing hold up under broader scrutiny from researchers and clinicians. - Ongoing interest in autophagy and longevity medicine may keep Cellitas in similar scientific discussions.